H.C. Wainwright Reiterates Their Hold Rating on Angion Biomedica (ANGN)

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Angion Biomedica (ANGNResearch Report) today. The company’s shares closed last Monday at $0.99, close to its 52-week low of $0.98.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -37.8% and a 18.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Timber Pharmaceuticals.

Currently, the analyst consensus on Angion Biomedica is a Hold with an average price target of $1.50.

See today’s best-performing stocks on TipRanks >>

Based on Angion Biomedica’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.65 million and GAAP net loss of $14.24 million. In comparison, last year the company earned revenue of $371K and had a GAAP net loss of $36.69 million.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body’s protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.

Read More on ANGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More